The phase 3 program missed both primary and key secondary endpoints, with no statistically significant effects on relevant measures observed for patients receiving investigational treatment ...
according to the final results of the Phase III KATHERINE clinical trial led by researchers from the University of Pittsburgh and UPMC Hillman Cancer Center. "KATHERINE is a landmark clinical ...
With dosing already underway, the next cohort in the Phase 1 study will provide additional insight into the development of this unprecedented approach to harnessing the power of FABP inhibition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback